Rucaparib (Rubraca) is a potent PARP inhibitor and approved as a monotherapy treatment for patients with BRCA-mutated (germline and/or somatic), platinum-sensitive or relapsed ovarian cancer and castration-resistant prostate cancer [31]. Here, PARP1 is linked to prostate cancer.